Lubiprostone: A chloride channel activator

Journal of Clinical Gastroenterology

Volumn 41, Issue 4, 2007, Pages 345-351

  Lacy, Brian E ^a   Campbell Levy, L ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Chloride; Chloride channels; Constipation; Functional bowel disorders; Gastrointestinal motility; Intestinal secretion; Irritable bowel syndrome; Lubiprostone

Indexed keywords

CHLORIDE CHANNEL; LUBIPROSTONE; OPIATE;

ABDOMINAL CRAMP; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DETERMINATION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DYSPEPSIA; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; HEADACHE; HUMAN; INTESTINE FLUID; INTESTINE ISCHEMIA; INTESTINE SECRETION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VOMITING;

ALPROSTADIL; CATHARTICS; CHLORIDE CHANNELS; CHLORIDES; CHRONIC DISEASE; CONSTIPATION; FATTY ACIDS; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; MALE;

EID: 34147173976     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225665.68920.df     Document Type: Review

References (41)

1. Kellow JE, Azpiroz F, Delvaux M, et al. Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology. 2006;130:1412-1420.
2. Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother. 2003;11:2089-2098.
3. Lacy BE, Yu S. Tegaserod: a new 5-HT4 agonist. J Clin Gastroenterol. 2002;34:27-33.
4. Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;4:429-440.
5. Lacy BE, Weiser K. Gastrointestinal motility disorders: an update. Dig Dis. 2006;24:228-242.
6. Kunzelmann K. The cystic fibrosis transmembrane conductance regulator and its function in epithelial transport. Rev Physiol Biochem Pharmacol. 1999;137:1-70.
7. Puljak L, Kilic G. Emerging roles of chloride channels in human diseases. Biochim Biophys Acta. 2006;1762:404-413.
8. Jentsch TJ, Neagoe I, Scheel O. ClC chloride channels and transporters. Curr Opin Neurobiol. 2005;15:319-325.
9. Jentsch TJ, Poet M, Fuhrmann JC, et al. Physiological functions of ClC Cl- channels gleaned from human genetic disease and mouse models. Annu Rev Physiol. 2005;67:779-807.
10. Suzuki M, Morita T, Iwamoto T. Diversity of Cl channels. Cell Mol Life Sci. 2006;63:12-24.
11. Mindell JA, Maduke M. ClC chloride channels. Genome Bio. 2001;2:3003.1-3003.6.
12. Chen TY. Structure and function of chloride channels. Annu Rev Physiol. 2000;67:809-839.
13. Lipecka J, Bali M, Thomas A, et al. Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol 2002;282:C805-C816.
14. - channels in rabbit gastric mucosa. Am J Physiol Cell Physiol. 2000;28:C1599-C1606.
15. Cuppoletti J, Tewari KP, Sherry AM, et al. ClC-2 channels in human lung epithelia: activation by arachadonic acid, amidation, and acid-activated omeprazole. Am J Physiol Cell Physiol. 2001;281:C46-C54.
16. Roman RM, Smith RL, Feranchak AP et al. Clc-2 chloride channels contribute to HTC cell volume homeostasis. Am J Physiol Gastrointest Liver Physiol. 2001;280:G344-G353.
17. Britton FC, Hatton WJ, Rossow CF, et al. Molecular distribution of volume-regulated chloride channels (ClC-2 and ClC-3) in cardiac tissues. Am J Physiol Heart Circ Physiol. 2000;279:H2225-H2233.
18. Enz R, Ross BJ, Cutting GR. Expression of the voltage-gated chloride channel ClC-2 in rod bipolar cells of the rat retina. J Neurosci. 1999;19:9841-9847.
19. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287:C1173-C1183.
20. Gyomorey K, Yeger H, Ackerley C, et al. Expression of the chloride channel ClC-2 in the murine small intestine epithelium. Am J Physiol Cell Physiol. 2000;279:C1787-C1794.
21. Catalan M, Cornejo I, Figueroa CD, et al. ClC-2 in guinea pig colon: mRNA, immunolabeling, and functional evidence for surface epithelium localization. Am J Physiol Gastrointest Liver Physiol. 2002;283:G1004-G1013.
22. Takeda drug insert. Available at: http://www.amitiza.com/ resources/pi.pdf. Accessed August 20, 2006.
23. Crawford DF, Perentesis GP, Engelke KJ, et al. Pharmacokinetic profile of lubiprostone, a selective GI chloride channel activator, after a single oral dose in multiple animal species. Am J Gastro. 2005;100:A901.
24. Perentesis GP, Crawford DF, Engelke KJ, et al. In vivo metabolism of lubiprostone, a novel GI chloride channel activator, in mouse, rat, dog, and monkey. Am J Gastroenterol. 2005; 100: A904.
25. Grider JR, Jin JG. Distinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulation. J Neurosci. 1994;14:2854-2860.
26. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942-G947.
27. Ueno R, Osama H, Habe T, et al. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology. 2004;126:A298-AM1109.
28. Johanson JF, Gargano MA, Patchen ML, et al. Efficacy and safety of a novel compound, RU-2011, for the treatment of constipation. Gastroenterology. 2002;122:A315.
29. Johanson JF, Gargano MA, Holland PC, et al. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology. 2003;126:A48.
30. Johanson JF, Gargano MA, Holland PC, et al. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week phase III study. Am J Gastroenterol. 2005;100:A884.
31. Johanson JF, Gargano MA, Holland PC, et al. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primary efficacy. Am J Gastroenterol. 2005;100:A896.
32. Johanson JF, Gargano MA, Holland PC, et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology. 2004;126:A298.
33. Johanson JF, Panas R, Holland PC, et al. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterology. 2006;130:A317.
34. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs. non-elderly subjects. Gastroenterology. 2006;130:A189.
35. Ueno R, Panas R, Wahle A, et al. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterology. 2006;130:A188.
36. Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs. female subjects. Gastroenterology. 2006;130:A322.
37. Ueno R. Multiple, escalating, oral-dose study to assess the safety, tolerance, and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motil. 2005;17:626.
38. Crawford DF, Perentesis GP, Engelke KJ, et al. Effects of lubiprostone, a novel GI chloride channel activator, on reproductive and developmental toxicity endpoints in rats. Am J Gastroenterol. 2005;100:A905.
39. Johanson JF, Panas R, Holland PC, et al. A dose-ranging, doubleblind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (c-IBS). Gastroenterology. 2006;130:A25.
40. Ueno R, Hiroyoshi O, Engelke KJ. Effect of lubiprostone on morphine-induced constipation and analgesia. Gastroenterology. 2006;130:A373.
41. Moeser AM, Engelke K, Perentesis GP, et al. Recovery of a mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, SPI-0211. Gastroenterology. 2005;100:A539.